Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News
  • Published:

Industry warily eyes new Medicare drug plan

Nature Biotechnology volume 24, page 120 (2006)Cite this article

A new subsection of Medicare known as Part D was launched under intense industry scrutiny.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

Author information

Authors and Affiliations

  1. Washington, DC

    Brian Vastag

Authors
  1. Brian Vastag
    View author publications

    Search author on:PubMed Google Scholar

Related links

Related links

Related links in Nature Research

https://doi.org/10.1038/NatureBiotechnology21,1119-1120(01Oct2003)nbt878

Biogenerics standoff

Industry ponders reimbursement crisis

Web links

Medicare

Centers for Medicare and Medicaid Services

Rights and permissions

Reprints and permissions

About this article

Cite this article

Vastag, B. Industry warily eyes new Medicare drug plan. Nat Biotechnol 24, 120 (2006). https://doi.org/10.1038/nbt0206-120

Download citation

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/nbt0206-120

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing